Hudson Value Partners LLC Decreases Stake in Johnson & Johnson $JNJ

Key Points

• Hudson Value Partners LLC reduced its stake in Johnson & Johnson by 12.0%, owning 33,722 shares after selling 4,602 shares in the second quarter.
• Analysts have increased their price targets for Johnson & Johnson, with Bank of America and UBS both setting a target of $198.00 and maintaining a neutral rating.
• Johnson & Johnson reported earnings of $2.77 per share in its latest quarterly results, exceeding analysts' expectations and achieving a year-over-year revenue increase of 5.8%.

Hudson Value Partners LLC lessened its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 12.0% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 33,722 shares of the company's stock after selling 4,602 shares during the quarter. Johnson & Johnson accounts for 1.8% of Hudson Value Partners LLC's investment portfolio, making the stock its 19th largest position. Hudson Value Partners LLC's holdings in Johnson & Johnson were worth $5,151,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Nuveen LLC purchased a new position in Johnson & Johnson during the 1st quarter valued at about $1,369,188,000. Bank of New York Mellon Corp grew its position in shares of Johnson & Johnson by 26.4% in the first quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock valued at $3,844,580,000 after purchasing an additional 4,842,582 shares during the last quarter. Pacer Advisors Inc. increased its stake in shares of Johnson & Johnson by 1,382.0% during the 1st quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company's stock worth $502,509,000 after purchasing an additional 2,825,626 shares in the last quarter. Assenagon Asset Management S.A. raised its position in shares of Johnson & Johnson by 159.6% during the 2nd quarter. Assenagon Asset Management S.A. now owns 4,159,260 shares of the company's stock worth $635,327,000 after purchasing an additional 2,557,388 shares during the last quarter. Finally, Kingstone Capital Partners Texas LLC purchased a new stake in Johnson & Johnson in the 2nd quarter valued at approximately $401,420,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Bank of America boosted their price target on Johnson & Johnson from $175.00 to $198.00 and gave the stock a "neutral" rating in a report on Friday. UBS Group set a $198.00 target price on shares of Johnson & Johnson in a research note on Friday. The Goldman Sachs Group raised their price target on shares of Johnson & Johnson from $185.00 to $186.00 and gave the stock a "buy" rating in a research note on Friday, September 19th. Royal Bank Of Canada boosted their price objective on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a research report on Thursday, July 17th. Finally, Wall Street Zen raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Saturday, September 13th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have issued a Hold rating to the company's stock. According to data from MarketBeat, Johnson & Johnson has an average rating of "Moderate Buy" and an average target price of $187.47.

Johnson & Johnson Price Performance

JNJ opened at $188.51 on Friday. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $189.78. The company's 50 day simple moving average is $176.18 and its 200 day simple moving average is $162.83. The stock has a market capitalization of $453.98 billion, a PE ratio of 20.16, a P/E/G ratio of 2.37 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. The company had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. Johnson & Johnson's revenue was up 5.8% on a year-over-year basis. During the same quarter last year, the firm posted $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, sell-side analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were paid a dividend of $1.30 per share. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.8%. Johnson & Johnson's dividend payout ratio is currently 55.61%.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company's stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.